Homocysteine and serum lipids concentration in male war veterans with posttraumatic stress disorder.

The evidence of increased cardiovascular disease (CVD) risk in posttraumatic stress disorder (PTSD) is accumulating. The present study aimed to determine whether chronic, combat-related PTSD is associated with serum lipid and homocysteine concentrations that could indicate higher CVD risk. The authors tested 66 war veterans with PTSD, 33 war veterans without PTSD, and 42 healthy volunteers for serum concentrations of homocysteine, total cholesterol, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and triglycerides. All the subjects were men and the analyses were adjusted for age, body mass index and smoking. Potential influences of depression, anxiety, and psychotic symptoms on the outcome measures were checked by introducing the scores from the Hamilton Depression Rating Scale (HAM-D-17), the Hamilton Anxiety Scale (HAMA), and the Positive and Negative Syndrome Scale (PANSS) into the overall statistical model. No differences in total cholesterol, LDL-C, HDL-C and triglycerides were found between the groups. Non-smoking PTSD war veterans had higher homocysteine concentrations (mean=10.4 micromol/L, SD=1.7) when compared to non-smoking war veterans without PTSD (mean=8.2 micromol/L, SD=4.0, P=0.014) and both smoking (mean=8.7 micromol/L, SD=2.3, P=0.008) and non-smoking healthy volunteers (mean=8.8 micromol/L, SD=2.2, P=0.021). The results of our cross-sectional study are possibly confounded by many factors, especially behavioral and life-style related which are difficult to control comprehensively and might have influenced serum lipids and homocysteine concentration in a complex manner. An increase in the homocysteine concentration observed in the non-smoking PTSD patients needs further investigation with a carefully designed prospective study to confirm associated, possibly enhanced CVD risk.

Use of non-invasive neuroradiological methods in research of psychoactive drugs.

Non-invasive neuroradiological methods like magnetic resonance spectroscopy (MRS), functional magnetic resonance imaging (fMRI), blood oxgenation level dependent (BOLD) imaging recently entered into the areas of research in psychiatry, psychoactive drug development, as well as in clinical practice. fMRI can identify the regions of the brain associated with various functions, can monitor recovery, progression, and response to treatment and MRS can be used to study brain chemistry and metabolism. BOLD-imaging provides an indirect indication of neuronal activity. Future developments of different neuroimaging techniques are promising not only in surgical planning, functional assessment in brain tumor management, monitoring functional changes, but also in discovery of pathophysiology of psychiatric disorders and recognition of new pharmacological targets. Those techniques could be implemented in the process of drug discovery and identification of biomarkers which are clinically relevant for development of candidate drugs. Furthermore, those techniques establish the bridge between preclinical and clinical studies and allow the drug research in human in vivo.